Ozempic vs Farxiga
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| US Ozempic | US Farxiga | |
|---|---|---|
| Generic name | semaglutide | dapagliflozin |
| Drug class | GLP-1 Receptor Agonist | SGLT2 Inhibitor |
| Treats | Type 2 diabetes | Type 2 diabetes, heart failure, chronic kidney disease |
| Category | Diabetes | Diabetes |
| Manufacturer | Novo Nordisk | AstraZeneca |
| Year approved | 2017 | 2014 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | $420M | $220M |
| Common side effects | Nausea, Vomiting, Diarrhea, Abdominal pain | Genital yeast infections, Urinary tract infections, Dehydration, Low blood pressure |
Frequently asked questions
Is Ozempic or Farxiga better?
Neither is universally "better." Ozempic (semaglutide) and Farxiga (dapagliflozin) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Ozempic and Farxiga?
Ozempic is a GLP-1 Receptor Agonist made by Novo Nordisk, while Farxiga is a SGLT2 Inhibitor made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Ozempic has the larger estimated TV advertising budget of the two.